Advertisement

Topics

AbbVie's Mavyret Is First 8-Week Pan-Genotypic Combination For HCV

14:10 EDT 3 Aug 2017 | SCRIP

FDA approval of the glecaprevir/pibrentasvir combination could help AbbVie fill a gap resulting from declining sales of Viekira Pak, while...

       

Original Article: AbbVie's Mavyret Is First 8-Week Pan-Genotypic Combination For HCV

NEXT ARTICLE

More From BioPortfolio on "AbbVie's Mavyret Is First 8-Week Pan-Genotypic Combination For HCV"

Quick Search
Advertisement
 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...